@article{03cb7ab4250c42958dab94124cef8f28,
title = "Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Gpnmb is classified as a type 1 membrane protein and its soluble form is secreted by ADAM10-mediated cleavage. Gpnmb mRNA was found in the Kupffer cells and white adipose tissues (WATs) and its upregulation in obesity was recently found. Here, we generated aP2 promoter-driven Gpnmb transgenic (Tg) mice and the overexpression of Gpnmb ameliorated the fat accumulation and fibrosis of the liver in diet-induced obesity model. Soluble form of Gpnmb in sera was elevated in Gpnmb Tg mice and Gpnmb concentrated in hepatic macrophages and stellate cells interacted with calnexin, which resulted in the reduction of oxidative stress. In the patients with non-alcoholic steatohepatitis, serum soluble GPNMB concentrations were higher compared with the patients with simple steatosis. The GPNMB is a promising biomarker and therapeutic target for the development and progression of NAFLD in obesity.",
author = "Akihiro Katayama and Atsuko Nakatsuka and Jun Eguchi and Kazutoshi Murakami and Sanae Teshigawara and Motoko Kanzaki and Tomokazu Nunoue and Kazuyuki Hida and Nozomu Wada and Tetsuya Yasunaka and Fusao Ikeda and Akinobu Takaki and Kazuhide Yamamoto and Hiroshi Kiyonari and Hirofumi Makino and Jun Wada",
note = "Funding Information: Competing financial interests: HM is a consultant for AbbVie, Astellas and Teijin, receives speaker honoraria from Astellas, Boehringer-ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Takeda, and Tanabe Mitsubishi, and receives grant support from Astellas, Boehringer-Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, Mochida, MSD, Novartis, Novo Nordisk, Pfizer, Takeda, and Tanabe Mitsubishi. JW is a consultant for Astellas, receives speaker honoraria from Novartis, Boehringer Ingelheim, Novo Nordisk and Tanabe Mitsubishi, and receives grant support from Tanabe Mitsubishi. Funding Information: This work was supported by JSPS Grant-in-Aid for 26293218, 26461361, and 26461362). Publisher Copyright: {\textcopyright} 2015, Nature Publishing Group. All rights reserved.",
year = "2015",
month = nov,
day = "19",
doi = "10.1038/srep16920",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
}
